Christenson Eric, Christenson Robert H
aDepartment of Medicine, Johns Hopkins Hospital bDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Coron Artery Dis. 2013 Dec;24(8):698-704. doi: 10.1097/MCA.0000000000000047.
Cardiac troponin I (cTnI) and T (cTnT) have displaced myoglobin and creatine kinase-MB as the preferred markers of myocardial injury and have become the cornerstones for diagnosis of myocardial infarction (MI). Current guidelines for MI diagnosis give specific recommendations for cTnI and cTnT assays including instructions to reliably measure values in the range of the 99th percentile of a normal reference cohort with good precision, for example, 10% total coefficient of variation. Unfortunately, the nomenclature system that has evolved for cTnI and cTnT is haphazard and unsystematic. It is key to recognize that not all cTnI and cTnT measurement methods are equivalent; hence, knowledge of local measurements is essential for effective evaluation of patients presenting with suspected non-ST elevation MI. For cTnI, the amino acid sequences frequently targeted for effective measurement include residues 41-49 and 83-93 because these regions of the molecule are stable, helping make the assays reproducible. Use of the recommended cutoff at the 99th percentile of a normal cohort is related to improved patient outcomes. Therefore, use of a troponin assay with good measurement characteristics at the 99th percentile, often referred to as 'sensitive assays', is important for patient outcomes. cTnI and cTnT assays with higher sensitivity are becoming available, and their utilization for measurement in asymptomatic populations may be useful for risk assessment and management in the future. However there is currently no evidence that these high-sensitivity assays confer an advantage in the context of MI diagnosis. Currently cTnI assays are not standardized; thus, there can be a substantial difference in values depending on the assay used. An international effort toward standardization is ongoing, but is not anticipated to be completed and implemented for a few years. Our purpose here is to add insight to important characteristics of troponin measurement techniques and how these features may impact clinical utilization of these tests.
心肌肌钙蛋白I(cTnI)和心肌肌钙蛋白T(cTnT)已取代肌红蛋白和肌酸激酶同工酶MB,成为心肌损伤的首选标志物,并已成为诊断心肌梗死(MI)的基石。目前的MI诊断指南对cTnI和cTnT检测给出了具体建议,包括要求以良好的精密度可靠测量正常参考队列第99百分位数范围内的值,例如,总变异系数为10%。不幸的是,针对cTnI和cTnT发展起来的命名系统是随意且不系统的。关键是要认识到并非所有的cTnI和cTnT测量方法都是等效的;因此,了解当地的测量方法对于有效评估疑似非ST段抬高型MI的患者至关重要。对于cTnI,有效测量经常靶向的氨基酸序列包括41 - 49位残基和83 - 93位残基,因为分子的这些区域是稳定的,有助于使检测具有可重复性。使用正常队列第99百分位数的推荐临界值与改善患者预后相关。因此,使用在第99百分位数具有良好测量特性的肌钙蛋白检测方法,通常称为“敏感检测”,对患者预后很重要。具有更高灵敏度的cTnI和cTnT检测方法正在出现,它们在无症状人群中的测量应用可能对未来的风险评估和管理有用。然而,目前没有证据表明这些高灵敏度检测方法在MI诊断方面具有优势。目前cTnI检测方法尚未标准化;因此,根据所使用的检测方法,值可能存在很大差异。正在进行一项国际标准化努力,但预计在几年内无法完成和实施。我们在此的目的是深入了解肌钙蛋白测量技术的重要特征以及这些特征可能如何影响这些检测的临床应用。